华东医药：全资子公司获得美国FDA药物临床试验批准通知书

Core Viewpoint - Huadong Medicine's subsidiary, Hangzhou Sino-American Huadong Pharmaceutical Co., has received FDA approval for the clinical trial of HDM2017, aimed at treating advanced malignant solid tumors [1] Group 1: Company Developments - The FDA has approved the clinical trial application for HDM2017, allowing the company to conduct Phase I trials in the U.S. [1] - As of the first half of 2025, Huadong Medicine's revenue composition is as follows: 68.23% from commercial brokerage and agency, 33.94% from pharmaceutical manufacturing, 4.57% from medical aesthetics, and 0.77% from other businesses, with inter-segment eliminations at -7.5% [1] - The current market capitalization of Huadong Medicine is 73.7 billion yuan [1]